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Summary Cytokinetic parameters of various types of lung cancer were determined in bronchoscopy speci-
mens after in vivo labelling with the thymidine analogue bromodeoxyuridine (BrdU). The S-phase fraction and
BrdU labelling index were measured flow cytometrically, allowing calculation of the S-phase transit time and
potential tumour doubling time. The methodology used was found to be feasible for obtaining cytokinetic data
from 76% of the bronchial biopsy samples.
Despite the difference in clinical behaviour and growth pattern between small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC), no significant differences were observed between the mean values of the
cytokinetic parameters of SCLC and NSCLC. The estimated cell loss factor was higher in NSCLC than in
SCLC.
It appears that the growth of a tumour, as clinically observed, is to a considerable extent influenced by cell
loss. In accord with this assumption is the fact that we have observed non-BrdU labelled S-phase cells, both in
tumour biopsies and in apparently normal tissue. The presence of these so-called unlabelled S-phase cells in
relation to cell loss is discussed.
Individual lung cancers differ in histological pattern and
other phenotypic characteristics. These differences are
relevant in predicting therapeutic responsiveness and prog-
nosis (Fraire et al.,1992). In recent years it has become
evidence that in lung cancer as well as in other types of
malignancy, cell cycle parameters may be important prognos-
ticators (Tubiana & Courdi, 1989). In several studies, a high
S-phase fraction (SPF) was found to be associated with a
shorter survival time (Ten Velde et al., 1988; Volm et al.,
1985); this was also found for tumours other than lung
carcinoma, including breast carcinoma (Kallioniemi et al.,
1986; O'Reilly et al., 1990). In addition, a low ex vivo
thymidine labelling index in patients with stage I NSCLC
predicts a longer survival time (Silvestrini et al., 1991).
Ex vivo labelling assays, as used in some of the studies
described above, are sensitive to technical variability since
they rely on the ex vivo continuation of DNA synthetic
activity and on an efficient incorporation of the label. Also,
measurements of SPF and ex vivo labelling index (LI) do not
allow the estimation of dynamic cytokinetic parameters such
as the S-phase transit time (Ts) and the potential tumour
doubling time (Tpot).
A more accurate and comprehensive description of cyto-
kinetic behaviour is possible by in vivo labelling of tumour
cells with the thymidine analogue bromodeoxyuridine
(BrdU). If some time is allowed to elapse between pulse
labelling and sampling, it is possible to determine cell kinetic
properties over time from a single sample (Begg et al., 1985;
Carlton et al., 1991). In this study, the feasibility of this
methodology in the cytokinetic analysis of bronchoscopy
specimens is described. The first results indicate that cell loss
may play a more significant role in determining the growth
rate of lung tumours than has been assumed so far.
Materials and methods
Patient material
Patients selected for this study were suspected for endobron-
chial lung carcinoma and scheduled for bronchoscopy. After
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informed consent, the patients were infused with 50 mg m-2
BrdU (Janssen Pharmaceutica, Beerse, Belgium), dissolved in
100 ml 0.9% NaCI, within a timespan of 10 min. The BrdU
was given approximately 4 to 5 h before bronchoscopy. App-
roval for the in vivo labelling method was given by the ethical
committee of the University Hospital of Maastricht. Biopsies
were taken with a flexible bronchoscope, fixed in formalin for
routine diagnosis and in 70% ethanol for flow cytometric
analysis. The latter samples were stored at 4°C until use.
Flow cytometry and BrdU detection
The biopsy specimens were double-stained with anti-BrdU
(clone IIbS; Schutte et al., 1987) and propidium iodide (PI),
using the protocol described by Schutte et al. (1987). Briefly,
ethanol fixed biopsies were minced in a petri dish and washed
twice in phosphate buffered saline (PBS) pH 7.4, by cent-
rifugation for 5 min at 400g. To obtain nuclei, the cell
suspension was digested with 0.4 mg ml-' pepsin (Boehringer
Mannheim, Germany; 108057) in 0.1 N HCI for 30 min at
room temperature. Undigested fragments were then removed
by sieving through a 50fim nylon mesh. After a washing step
in PBS, the supernatant was removed and the pellet
incubated in 2 ml 2 N HCI, for 30 min at 37°C. The nuclear
suspension was then washed twice in Borax buffer (0.1 M
sodiumtetraborate, pH 8.5), and once in PBS containing
0.1% bovine serum albumin (BSA) and 0.1% sodium azide
(NaN3). The pelleted nuclei were resuspended in 100 All
monoclonal anti-BrdU antibody, appropriately diluted in
PBS/BSA/NaN3, and incubated for 60 min at room
temperature followed by two washing steps in PBS/BSA/
NaN3. Primary antibody binding was visualised by
incubating the pellet with 100flI 1:20 diluted FITC con-
jugated Fab2 fragments of rabbit anti-mouse IgG (DAKO-
PATTS, Glostrup, Denmark; F313) for 60 min at room
temperature in the dark. After washing twice in PBS/BSA/
NaN3, the nuclei were finally.counterstained with 0.5 ml of a
10 lOg ml-' propidium iodide (Calbiochem, La Jolla, CA;
537059) solution in PBS containing 0.1 mg ml-' RNase
(Serva, Heidelberg, Germany). After incubation for at least
15min in the dark, the samples were analysed using the
FACS IV flow cytometer (Becton & Dickinson, Sunnyvale,
CA, USA). A total number of 5000 nuclei per sample were
recorded.
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Calculation ofcytokinetic parameters
The DNA index (DI) was estimated from the single
paramater DNA histograms. In case of one GI peak the
sample was defined as diploid and the DNA index was
considered 1.0; in case of two GI peaks the sample was
defined as aneuploid and the DNA index was calculated by
dividing the channel number of the right-sided peak to the
channel number of the left-sided one, according to Hiddeman
et al. (1984). The S-phase fraction (SPF) was determined
from the DNA histogram using the rectangular fit method
described by Baisch et al. (1982). To calculate the S-phase
transit time (Ts), the relative movement (RM) of the labelled
cells during the BrdU chase time t (=the time passed
between administration of the BrdU pulse and fixation after
bronchoscopy) was measured according to Begg et al. (1985).
In formula, the relative movement is defined by:
RM- FL-FG,
FG2-FG,
where FL is the mean DNA content of labelled undivided
cells and FG, and FG2 the mean DNA contents of the GI and
G2 phase cells, respectively.
From the chase time t and the relative movement, the S-
phase transit time (Ts) can be estimated as follows:
0.5
T = 05 * t
RM-0.5
Furthermore, on basis of these parameters the potential
doubling time (Tpot) of the tumour can be defined according
to White et al. (1990) as:
Tpot= n2* Ts
vs
with
v= In + 1 fIU(t)
1 (f )d(t)/2)
and with ftU being the fraction labelled undivided cells, and Pd
being the fraction labelled divided cells.
The labelling index (LI) was defined as the percentage of
BrdU positive cells. No corrections were made for labelled
cells in GI that had undergone cell division in the period
between administration of the BrdU and sampling of the
biopsy.
Results
Fifty patients entered the study (42 male, eight female;
median age 68, range 44-82). Full analysis was possible in
38 cases; in 12 patients DNA analysis could be performed
but the labelling results were of too poor quality to allow
conclusions. Of the patients with malignant disease the
expected one-quarter of the patients had small cell lung
cancer, and around three-quarters of these patients had
disease limited to the thorax (Table I).
Ploidy characteristics are given in Table II. Of all biopsies
that contained malignant cells (n = 32), 38% appeared to
contain an aneuploid stemline; the median relative size of the
Table II Ploidy characteristics of bronchoscopy specimens
Aneuploid
No malignancy
Non malignant biopsy from
patients with malignancy
All malignant biopsies
SCLC
squamous
adeno
LCLC
0/4
1/14
12/32
1/9
6/10
1/5
4/8
aneuploid population in these samples was 21%. In only one
of 14 histologically tumour-negative biopsies from patients
with lung cancer, an aneuploid population could be detected.
For the cytokinetic analysis we divided the 38 fully evaluable
patients into three groups; no malignant disease (n = 2), his-
tologically tumour-negative biopsies from patients with
malignant disease (n = 9) and biopsies containing malignant
cells, including the one biopsy that was histologically
negative but contained aneuploidy (n = 27). Data on S-phase
fractions as calculated from the univariate DNA histogram,
labelling index with BrdU as calculated from the univariate
BrdU-fluorescence analysis and the duration of S-phase and
the potential doubling time as calculated from the bivariate
analysis are given in Table III. Between biopsies with no
malignancy and non-malignant biopsies from patients with
malignancy, no differences were observed. Malignant biopsies
showed a higher SPF (n.s.), a significantly higher LI
(P = 0.01), equal Ts and significantly shorter potential doubl-
ing time (P = 0.0014). Within the group of malignant biop-
sies no differences were observed; in particular, the mean
potential doubling time of SCLC was 207h, which is not
significantly different from the mean Tpot of 194 h for
NSCLC.
We next compared the cytokinetic characteristics for dip-
loid and aneuploid tumours and included also the group of
lung cancer patients with non-malignant, diploid biopsies
(Table IV). The potential doubling time appears to decrease
in the order of non-malignant tissue, diploid tumours and
aneuploid tumours. This occurred despite the fact that
aneuploid tumours had a longer S-phase transit time and
therefore can only be explained by their high labelling index.
In all samples the SPF appeared to exceed the LI to a
considerable extent. We therefore investigated whether these
two potential parameters of S-phase activity are indeed inter-
related. In Figure 1 the correlation between LI and SPF is
given for all samples with full analysis (n = 38). The two
parameters correlated significantly (r = 0.77), but at the level
ofindividual samples the SPF almost always exceeded the LI.
This suggests the presence of a considerable number of cells
with S-phase DNA content without the ability to incorporate
BrdU; we called these cells 'unlabelled S-phase cells'. The
presence of unlabelled S-phase cells could be a tumour char-
acteristic with prognostic or therapeutic implications. An
example of the presence of a considerable population of cells
with S-phase DNA content but without incorporated BrdU is
given in Figure 2. We developed methodologies to quantify
their frequency by determining an 'unlabelled S-phase frac-
tion' or USPF, indicating the fraction of all cells with S-
phase DNA content that do not label. This was done using
the following formula:
Table I Final diagnosis and stage of disease of patients with lung cancer
Diagnosis Number LDa EDa P II III IV Unknown
SCLC 12 (9)c 8 4 0
Squamous 14 (10) 3 3 4 3 1
Adeno 8 (5) 1 1 6 0
LCLC 12 (8) 1 6 2 3
Not malignant 4 (4)
aLimited or extensive disease, respectively. 'Staging according to UICC criteria. cBetween brackets the
number of patients with this diagnosis in the biopsy used for cytokinetic analysis. A total number of 14
biopsies from patients with lung cancer was histologically tumour-negative.CYTOKINETIC ANALYSIS OF LUNG CANCER BY IN VIVO BRDU LABELLING 1219
Table III Cytokinetic characteristics of bronchoscopy specimens
USPF (%) USPF (%)
SPF (%) LI (%) Ts (h) Tpot (h) method method 2
Number Mean (range) Mean (range) Mean (range) Mean (range) Mean (range) Mean (range)
No malignancy 2 9.0 (9-9) 3.6 (1.1-6.1) 9.9 (7.7-12.0) 422 (113-730) 74 (61-87) 82 (71-92)
Non malignant diploid 9 8.4 (5-12) 2.7 (1.2-7.8) 11.1 (4.2-41.1) 414 (156-767) 68 (33-89) 85 (74-98)
biopsy from patients
with malignancy
All malignant biopsiesa 27 16.4 (6-44) 9.9b (1.1-33.6) 10.0 (3.6-29.4) 187b (36-670) 50b (19-81) 70b (36-99)
SCLC 7 11.6 (6-22) 7.0 (1.1-17.6) 9.0 (4.5-13.5) 207 (73-670) 50 (21-81) 67 (41-81)
squamous 10 23.1 (8-44) 12.1 (3.8-33.6) 12.3 (4.0-19.4) 171 (45-498) 51 (24-89) 70 (36-99)
adeno 3 12.0 (6-19) 11.7 (1.2-21.9) 6.4 (5.1-7.8) 205 (36-533) 48 (19-81) 80 (65-95)
LCLC 7 16.1 (7-24) 8.2 (1.3-18.4) 10.6 (3.6-29.4) 223 (45-571) 55 (22-81) 73 (54-86)
aIncluding one biopsy that was histologically normal but contained aneuploid cells. bSignificantly different from the two other categories of
patients in a Student's t test.
Table IV Cytokinetic characteristics of patients with malignancy in relation to ploidy status
SPF LI Ts Tpot
Number Mean (range) Mean (range) Mean (range) Mean (Range)
Non malignant diploid biopsy 9 8.4 (5-12) 2.7 (1.2-7.8) 11.1 (4.2-41.1) 414a (156-767)
from patients with malignancy
Diploid tumours 14 9.4 (6-17) 5.0 (1.1-11.9) 6.9 (3.6-13.5) 232 (45-670)
Aneuploid tumours 13 25.3a (14-44) 14.7a (3.8-33.6) 14.0b (5.7-29.4) 161 (36-498)
aSignificantly different from the two other categories of patients in a Student's t test. "Significantly different from the group of diploid
tumours in a Student's t test.
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Figure 1 Correlation between percentage BrdU positive cells
(labelling index; LI) and S-phase fraction (SPF) for all patients
with full analysis (n = 38). Correlation coefficient r = 0.77.
USPF = (SPF-LI)/SPF. This formula was applied to the
population at large (method 1) or to a representative portion
of the population by restricting the analysis to a small seg-
ment in the second part of the S-phase (method 2). The latter
method avoids the possible disturbing effect of cells that are
unlabelled because they entered the S-phase in the time
period between in vivo labelling and bronchoscopy.
Results of the two methods are given in Table III. It
appears that the two methods to estimate the USPF are
different in that method 2 gives higher estimates. However, in
the 3 groups of patients the results of the two methods show
a similar tendency; the correlation coefficient was found to be
0.7 (P = 5.9E-5). Whatever method used, the USPF appears
to be lower in malignant samples (P = 0.01 (method 1) or
P = 0.0064 (method 2)).
Discussion
The main goal of this study was to investigate the feasibility
of determining cytokinetic characteristics from human bron-
choscopy specimens. Therefore we entered a heterogeneous
group of patients encompassing the full spectrum of types
and stages of bronchial carcinoma as well as biopsies of
normal bronchial tissue. Fifty of such specimens were ade-
quate to the extent that patients were eligible and a nuclear
suspension of good enough quality for flow cytometric
analysis was obtained. Full analysis was possible in 76% of
all cases. The main reasons for not being able to perform
cytokinetic analysis was the failure to detect a coherent
cohort of labelled cells. In these samples very few cells (less
than 1%) were found labelled with BrdU and these cells were
randomly scattered over the dotplot. This occurred in 6/17
non-malignant and in 6/33 malignant specimens, indicating
that successful analysis is possible in an even higher percen-
tage of patients with malignant tumours. Acute side-effects
were not observed with the dose of BrdU employed, as has
also been the case in earlier studies with this dose and slightly
higher doses (Forster et al., 1992; Hoshino et al., 1985;
Hupperets et al., 1986; Miller et al., 1991; Nagashima et al.,
1988; Shimomatsuya et al., 1991; Ten Velde et al., 1989a;
Wilson et al., 1988).
During the course of this study, some problems have arisen
concerning flow cytometric analysis. Difficulties in discerning
the tumour cell population from other cell types present in
the bronchoscopy sample were manifest in particular in dip-
loid samples, where it is not possible to make a distinction
between normal cells or tumour cells with a diploid DNA
content. In aneuploid samples, the major problem was over-
lap of diploid and aneuploid populations. An additional
disturbing effect was generated by the accumulation of cell
debris in the sample. This makes estimations of cell numbers
in various phases of the cell cycle less reliable. In order to
avoid the problems mentioned above, we started to inves-
tigate the use of dual parameter image cytometry as an
alternative. This technique is currently being optimised. Begg
et al. (1991) recently described three-colour fluorescence flow
cytometry as a method for selecting the desired malignant
cell population for kinetic analysis, that also may be useful in
this respect.
One of the most striking results of this study is the finding
of a considerable number of cells with a DNA content
between GI and G2 that do not take up BrdU: the so-called
unlabelled S-phase cells. These cells were observed in vir-
tually each sample. Previously, the existence of this
phenomenon had also been described by Darzynkiewicz
(1986), Forster et al. (1992), Ten Velde et al. (1989a and b)
and Wilson et al. (1988), while an exceeding of the SPF over
the LI was reported by Meyer & Coplin (1988); Teodori et
al. (1990) and Wilson et al. (1985). We were concerned about
technical artefacts and therefore determined the frequency of
such cells (USPF) by restricting the analysis to a window
close to the G2/M peak. This eliminates the contribution of
cells that have entered the S-phase in the time between
labelling with BrdU and sampling of the biopsy, and would
also possibly decrease the influence of debris. Still, we found
that 36-99% of the S-phase cells were unlabelled. In inter-
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Figure 2 Aneuploid tumour biopsy sample. X-axis: DNA content; Y-axis: BrdU fluorescence.
preting these data it has to be taken into account, however,
that cell debris may still interfere with the estimation of the
USPF, in particular in diploid samples with a relatively low
frequency of labelled cells. This is due to the fact that cell
debris shows an exponential decline with relatively higher
counts in the lower DNA channels. This may in part explain
why normal tissues with a low LI were found to have a
higher USPF as compared to malignant biopsies.
The cause of S-phase cells not to incorporate the DNA
precursor BrdU can be 2-fold: either the cells are cycling but
the BrdU cannot reach them of the BrdU is present but the
cells do not cycle. The first possibility implies dose-related
problems. In a study with human bone marrow, Hupperets et
al. (1986) investigated the feasibility of in vivo labelling of
bone marrow cells with BrdU in doses varying from
700 mg m-2 to 50 mg m-2. They found that in vivo labelling
with 50 mg m-2 BrdU was safe, feasible and as effective as
higher doses. Furthermore, if dose was an issue, one would
expect to find cells with a labelling intensity varying between
negative and maximally positive rather than two distinct
populations with clearly negative and positive characteristics,
as we observed and as is illustrated in Figure 2. Finally,
Forster et al. (1992), using a higher dose of BrdU in a study
of squamous head and neck cancer, reported similar labelling
indices as well as the presence of unlabelled S-phase cells.
Morstyn et al. (1983) found a uniform BrdU distribution
in small melanoma, but a heterogeneous distribution of
BrdU in large melanoma which they ascribed to differences
in perfusion. This points to the possibility that the presence
of unlabelled S-phase cells is related to local dose problems,
due to the presence of areas with poor perfusion. In that
case, one would expect the cells that do label to pass through
the S-phase with a constant rate. In contrast, we found
variable durations of S-phase with some biopsies showing
extremely long S-phase transit times. It cannot be ruled out,
however, that at least part of the S-phase cells do not label
because of poor availability of BrdU.
A second possibility to explain the presence of unlabelled
S-phase cells could be that cells, for some reason, stop cycl-
ing during S-phase. Assuming that this is a random event,
this would imply that cells in the BrdU labelled population
will arrest also. According to the theoretical model developed
by White (1991), this will result in high values for Ts.
Therefore, the length of the S-phase transit time could be
another indicator for the presence of unlabelled S-phase cells.
From the data presented in Table III, it appears that
although the mean S-phase transit time did not differ
between the various groups, there always was a wide range
with some samples showing very long Ts. It remains to be
determined whether the duration of S-phase could be a better
indicator for the occurrence of cell arrest in S-phase than the
fraction of unlabelled S-phase cells, in particular in case of a
poor ratio between the degree of labelling and the presence
of debris. The background and clinical implications of
unlabelled S-phase cells are currently being investigated by
performing in vitro experiments subjecting tumour cells to
poor metabolic states.
When comparing various groups of samples, we found
significant differences in SPF, LI and potential doubling time
between malignant and non-malignant biopsies. Within the
various types of lung cancer, cytokinetic parameters did not
differ. Similarly, no significant differences were observed
between the two major groups of lung cancer; small cell lung
cancer (SCLC) and non small cell lung cancer (NSCLC). In
particular, potential doubling times did not differ (SCLC: 8.6
days; NSCLC: 8.1 days), whereas small cell lung tumours are
known to be clinically more aggressive and appear to double
their cell number at a higher rate than do cancers of the non
small cell type. This points to the possibility that the cell loss
factor is considerably higher in non small cell lung cancer
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than in small cell lung cancer. The mean tumour volume
doubling times for these types of lung cancer are approx-
imately 3 months (100 days) for NSCLC and 1 month (30
days) for SCLC (Selawry & Hansen, 1982). Our cytokinetic
data however, indicate a doubling of the cell number in 8.1
days (NSCLC) and 8.6 days (SCLC). Wilson et al. (1988),
who calculated the potential tumour doubling time in 25
solid human tumours, found an overall mean of only 5.5
days. A significant discrepancy between the calculated
tumour doubling time and the measured doubling time was
also reported by Terz et al. (1971). The cell loss factor can be
defined as (1-(Tp0,/Td)) x 100% (Steel, 1977), where Tpot is
the potential doubling time (assuming there is no cell loss)
and Td is the actual doubling time. Using this formula and
our data, the cell loss factor in NSCLC is estimated as to be
90%, whereas the cell loss in SCLC is estimated on 70%.
This is in accord with one previous report, in which the cell
loss of human tumours was found to range from 40% to
80%, with a higher cell loss in squamous cell lung carcinoma
than in small cell lung carcinoma (Shimomatsuya et al.,
1991). Taken together, our data strongly support the concept
that the relatively slow growth rate of NSCLC as compared
to SCLC does not depend on differences in proliferation but
rather on the rate of cell loss.
Reports in the literature, concerning Ki67 expression, show
no significant differences between SCLC and NSCLC,
although there seems to be a trend-towards a higher positive
Ki67 fraction in SCLC (Gatter et al., 1986, Soomroo &
Whimster, 1990). This is not in conflict with our hypothesis
that SCLC exhibit a lower cell loss factor than NSCLC, since
Ki67 is a protein which is expressed in proliferating cells.
However, it is a static marker which does not reflect active
proliferation and which therefore cannot be directly com-
pared to the cytokinetic parameters measured in this study.
We have demonstrated the feasibility of obtaining dynamic
cytokinetic data from bronchoscopy specimens after in vivo
labelling with BrdU in a majority of patients presenting with
lung cancer. Growth parameters such as the potential tumour
doubling time, the S-phase transit time and an estimation of
the presence of arrested S-phase cells can be obtained that
will now be assessed for their prognostic and therapeutic
implications.
This study was supported by a grant from the Dutch Cancer Society
(grant no. IKL-90-01).
References
BAISCH, H., BECK, H., CHRISTENSEN, I., HARTMANN, N., FRIED, J.,
DEAN, P., GRAY, J., JETT, J., JOHNSTON, D., WHITE, R.,
NICOLINI, C., ZIETZ, S. & WATSON J. (1982). A comparison of
mathematical methods for the analysis of DNA histograms
obtained by flow cytometry. Cell Tissue Kinet., 15, 235-249.
BEGG, A.C. & HOFLAND, I. (1991). Cell kinetic analysis of mixed
populations using three-color fluorescence flow cytometry.
Cytometry, 12, 445-454.
BEGG, A.C., MCNALLY, N.J., SCHRIEVE, D.C. & KARCHNER, H.
(1985). A method to measure the duration of DNA synthesis and
the potential doubling time from a single sample. Cytometry, 6,
620-626.
CARLTON, J.C., TERRY, N.H.A. & WHITE, R.A. (1991). Measuring
potential doubling times of murine tumors using flow cytometry.
Cytometry, 12, 645-650.
DARZYNKIEWICZ, Z. (1986). Cytochemical probes of cycling and
quiescent cells applicable to flow cytometry. In Techniques in Cell
Cycle Analysis, Gray, J.E. & Darzynkiewicz, Z. (eds) pp.
255-290. Human Press, Inc: Clifton, New Jersey.
FORSTER, G., COOKE, T.G., COOKE, L.D., STANTON, P.D., BOWIE,
G. & STELL, P.M. (1992). Tumor growth rates in squamous car-
cinoma of the head and neck measured by in vivo bromodeox-
yuridine incorporation and flow cytometry. Br. J. Cancer, 65,
698-702.
FRAIRE, A.E., JOHNSON, E.H., YESNER, R., ZHANG, X.B., SPJUT,
H.J. & GREENBERG, S.D. (1992). Prognostic significance of his-
topathologic subtype and stage in small cell lung cancer. Human
pathol., 23, 520-528.
GATTER, K.C., DUNNILL, M.S., GERDES, J., STEIN, H. & MASON,
D.Y. (1986). New approach to assessing lung tumours in man. J.
Clin. Pathol., 39, 590-593.
HIDDEMAN, W., SCHUMANN, J., ANDREEFF, M., BARLOGIE, B.,
HERMAN, C.J., LEIF, R.C., MAYALL, B.H., MURPHY, R.F. &
SANDBERG, A.A. (1984). Convention on nomenclature for DNA
cytometry. Cytometry, 5, 445-446.
HOSHINO, T., NAGASHIMA, T., MUROVIC, J., LEVIN, E.M., LEVIN,
V.A. & RUPP, S.M. (1985). Cell kinetic studies of in situ human
brain tumors with bromodeoxyuridine. Cytometry, 6, 627-632.
HUPPERETS, P.S.J.G., SCHUTTE, B., VAN ASSCHE, C., REIJNDERS,
M.M.J. & BLIJHAM, G.H. (1986). Proliferative characteristics of
human bone marrow cells following in vivo administration of
bromodeoxyuridine. Cancer Chemother. Pharmacol., 18, suppl. 1,
148.
KALLIONIEMI, O.P., HIETANEN, T., MATTILA, J., LEHTINEN, M.,
LAUSLAHTI, K. & KOIVULA, T. (1986). Aneuploid DNA content
and high S phase fraction of tumour cells are related to poor
prognosis in patients with primary breast cancer. Eur. J. Cancer
Clin. Oncol., 23, 277.
MEYER, J.S. & COPLIN, M.D. (1988). Thymidine labelling index, flow
cytometric S-phase measurement, and DNA index in human
tumors. Am. J. Clin. Path., 89, 586-595.
MILLER, M.A., MAZEWSKI, C.M., YOUSUF, N., SHEIKH, Y., WHITE,
L.M., YANIK, G.A., HYAMS, D.M., LAMPKIN, B.C. & RAZA, A.
(1991). Simultaneous immunohistochemical detection of lUdR
and BrdU infused intravenously to cancer patients. J. Histochem.
Cytochem., 39, 407-412.
MORSTYN, G., HSU, S.-M., KINSELLA, T., GRATZNER, H., RUSSO, A.
& MITCHELL, J.B. (1983). Bromodeoxyuridine in tumors and
chromosomes detected with a monoclonal antibody. J. Clin.
Invest., 72, 1844-1850.
NAGASHIMA, T., HOSHINO, T., CHO, K.G., EDWARDS, M.S.B., HUD-
GINS, R.J. & DAVIS, R.L. (1988). The proliferative potential of
human ependymomas measured by in situ bromodeoxyuridine
labeling. Cancer, 61, 2433-2438.
O'REILLY, S.M., CAMPLEJOHN, R.S., BARNES, D.M., MILLIS, R.R.,
ALLEN, D., RUBENS, R.D. & RICHARDS, M.A. (1990). DNA
index, S-phase fraction, histological grade and prognosis in breast
cancer. Br. J. Cancer, 61, 671-674.
SCHUTTE, B., REIJNDERS, M.M.J., VAN ASSCHE, C.L.M.V.J., HUP-
PERETS, P.S.J.G., BOSMAN, F.T. & BLIJHAM, G.H. (1987). An
improved method for the immunocytochemical detection of
bromodeoxyuridine labeled nuclei using flow cytometry.
Cytometry, 8, 372-376.
SELAWRY, O.S. & HANSEN, H.H. (1982). Respiratory tract cancer. In
Cancer Medicine, Holland, J.F. & Frei, E. (eds) pp. 1732, Lea &
Febiger: Philadephia.
SHIMOMATSUYA, T., TANIGAWA, N. & MURAOKA, R. (1991). Pro-
liferative activity of human tumors: assessment using bromodeox-
yuridine and flow cytometry. Jpn. J. Cancer Res., 82, 357-362.
SILVESTRINI, R., MUSCOLINO, G., COSTA, A., LEQUAGLIE, C.,
VENERONI, S., MEZZANOTTE, G. & RAVASI, G. (1991). Could
cell kinetics be a predictor of prognosis in non-small cell lung
cancer? Lung cancer, 7, 165-170.
SOOMROO, I.N. & WHIMSTER, W.F. (1990). Growth fraction in lung
tumours determined by Ki67 immunostaining and comparison
with AgNOR scores. J. Pathol., 162, 217-222.
STEEL, G.G. (1977). Growth kinetics of tumours, pp. 70-72. Claren-
don Press: Oxford.
TERZ, J.J., CURUTCHET, H.P. & LAWRENCE, W. (1971). Analysis of
the cell kinetics of human solid tumors. Cancer, 5, 1100-1110.
TEODORI, L., TRINCA, M.L., GOEHDE, W., HEMMER, J., SALVATI,
F., STORNIELLO, G. & MAURO, F. (1990). Cytokinetic investiga-
tion of lung tumors using the anti-bromodeoxyuridine (BUdR)
monoclonal antibody method: comparison with DNA flow
cytometric data. Int. J. Cancer, 45, 995-1001.
TEN VELDE, G.P.M., SCHUTTE, B., VERMEULEN, A., VOLOVICS, A.,
REIJNDERS, M.M.J. & BLIJHAM, G.H. (1988). Flowcytometric
analysis of DNA ploidy level in paraffin embedded tissue of
non-small lung cancer. Eur. J. Cancer Clin. Oncol., 24, 455-460.
TEN VELDE, G.P.M. (1989a). Cytokinetic analysis of lung cancer
specimens by in vivo bromodeoxyuridine labeling. In Thesis.
pp. 85-94. University of Limburg: Maastricht, The Netherlands.1222 M.M.F.J. TINNEMANS et al.
TEN VELDE, G.P.M., SCHUTTE, B., REIJNDERS, M.M.J., BOSMAN,
F.T. & BLIJHAM, G.H. (1989b). Cytokinetic analysis of lung
cancer by bromodeoxyuridine labeling of cytology specimens.
Cytometry, 10, 807-810.
TUBIANA, M. & COURDI, A. (1989). Cell proliferation kinetics in
human solid tumors: relation to probability of metastatic
dissemination and long-term survival. Radiother. Oncol., 15,
1-18.
VOLM, M., MATTERN, J., SONKA, J., VOGT-SCHADEN, M. & WAYSS,
K. (1985). DNA distribution in non-small-cell lung carcinomas
and its relationship to clinical behavior. Cytometry, 6, 348-356.
WHITE, R.A. (1991). A theory for analysis of cell populations with
non-cycling S phase cells. J. Theor. Biol., 150, 201-214.
WHITE, R.A., TERRY, N.H.A., MEISTRICH, M.L. & CALKINS, D.P.
(1990). Improved method for computing potential doubling time
from flow cytometric data. Cytometry, 11, 314-317.
WILSON, G.D., MCNALLY, N.J., DUNPHY, E., KARCHER, H. &
PFRAGNER, R. (1985). The labelling index of human and mouse
tumours assessed by bromodeoxyuridine staining in vitro and in
vivo and flow cytometry. Cytometry, 6, 641-647.
WILSON, G.D., MCNALLY, N.J., DISCHE, S., SAUNDERS, M.I., DES
ROCHERS, C., LEWIS, A.A. & BENNETT, M.H. (1988). Measure-
ment of cell kinetics in human tumours in vivo using bromodeox-
yuridine incorporation and flow cytometry. Br. J. Cancer, 58,
423-431.